Dose, wavelength, and protocol parameters for photobiomodulation across 27 clinical conditions. Every cell is sourced to peer-reviewed meta-analyses, Cochrane Library reviews, ClinicalTrials.gov registry data, or professional-society guidelines. Every reference is a verifiable PMID.
Published 2026-05-30 Last reviewed 2026-05-30Re-review cadence: every 26 weeks
Read before the table
Biphasic dose-response
Photobiomodulation follows a biphasic (Arndt-Schulz) dose-response curve: too little energy delivers no effect, and too much energy can reverse or inhibit the desired effect. Effective doses for most conditions fall in the 4-30 J/cm² window. Doses above approximately 60 J/cm² have been associated with reduced or reversed effect in multiple in-vitro and clinical studies.
How dose is measured
Dose (joules per square centimeter, J/cm²) is calculated as irradiance (mW/cm²) × time (seconds) ÷ 1000. The same dose can be delivered as a short high-irradiance session or a longer low-irradiance session, but pulsed vs continuous-wave delivery, beam coherence, and distance to skin all affect the effective dose at the target tissue depth. Cited references vary in how they report dose; we have normalized to surface J/cm² where the original study reported it explicitly.
Contraindications
PBM is generally well-tolerated but should be avoided over: (a) active malignancy in the treatment field, (b) the abdomen during pregnancy, (c) the thyroid in patients with hyperthyroidism, (d) skin lesions of unknown etiology. Photosensitizing medications (some antibiotics, retinoids, St. John's wort) may increase skin sensitivity; patients should consult their clinician before starting PBM.
Knee OA: 4-8 J at 785-860 nm or 1-3 J at 904 nm per treatment spot (Stausholm 2019); WALT per-joint: knee medial 12 J total (780-860 nm) or 6 J (904 nm); hip 12 J (780-860 nm) or 10 J (904 nm); RA hand joints 1-4 J/joint
Stausholm 2019 BMJ Open meta-analysis (22 RCTs, n=1063) established that LLLT at 4-8 J (785-860 nm) or 1-3 J (904 nm) per spot significantly reduces pain and disability in knee OA when WALT dose recommendations are followed. The Brosseau Cochrane reviews (RA 2005, OA 2004) found short-term reduction in pain and morning stiffness for RA and conflicting OA results that depend on dose application.
3 caveats + limitations
Knee OA evidence is stronger than RA evidence; the 2023 Lourinho meta-analysis (PLoS One) classified RA evidence as "very uncertain" with infrared possibly not superior to sham.
ACR 2019 OA guideline did not assess PBM as a discrete intervention; only AAOS 2021 explicitly endorses FDA-approved laser for knee OA pain and function.
Trials using doses outside the WALT window were ineffective — dose discipline matters.
“LLLT reduces pain and disability in KOA at 4-8 J with 785-860 nm wavelength and at 1-3 J with 904 nm wavelength per treatment spot.”
Brosseau L, Robinson V, Wells G, et al. (2005). Cochrane Database of Systematic Reviews. PMID:16235295 · DOI · cochrane
“LLLT could be considered for short-term treatment for relief of pain and morning stiffness for RA patients, particularly since it has few side-effects.”
Brosseau L, Welch V, Wells G, DeBie R, Gam A, Harman K, Morin M, Shea B, Tugwell P (2004). Cochrane Database of Systematic Reviews. PMID:15266461 · DOI · cochrane
“For OA, the results are conflicting in different studies and may depend on the method of application and other features of the LLLT application. Lower dosage of LLLT was found as effective than higher dosage for reducing pain and improving knee range of motion.”
Lourinho I, Sousa T, Jardim R, et al. (2023). PLoS One. PMID:37683021 · systematic-review
Last reviewed: 2026-05-30
Back Pain (lumbar, thoracic — chronic non-specific)
WALT lumbar spine: 16 J total / 4 J per point (780-860 nm); 4 J total / 2 J per point (904 nm); pooled meta-analysis dose 2-8 J/cm² per point but high heterogeneity
Wavelengths (nm)
780 · 810 · 830 · 904
Irradiance
5-500 mW (780-860 nm); >5 mW/cm² (904 nm)
Sessions / week
2-3
Duration → outcome
4-8 weeks
Huang 2015 meta-analysis (7 RCTs, n=394) found LLLT significantly reduced VAS pain vs placebo in chronic non-specific low back pain but no significant effect on disability/ROM. The 2008 Cochrane review (Yousefi-Nooraie) concluded the data are insufficient to draw firm conclusions, and NICE NG59 (2016/2020) explicitly notes uncertainty over laser therapy for low back pain.
3 caveats + limitations
Cochrane 2008 found insufficient evidence; NICE NG59 declined to endorse; APTA 2021 LBP CPG does not recommend LLLT as a primary intervention.
Huang 2020 independent SR concluded PBM does NOT decrease pain or disability in non-specific LBP — most trials did NOT follow WALT dose recommendations.
Dose-response not clearly characterized in pooled analyses; high heterogeneity across LLLT protocols.
References (2)
Huang Z, Ma J, Chen J, Shen B, Pei F, Kraus VB (2015). Arthritis Research & Therapy. PMID:26667480 · meta-analysis
Yousefi-Nooraie R, Schonstein E, Heidari K, et al. (2008). Cochrane Database of Systematic Reviews. PMID:18425909 · DOI · cochrane
“Based on the heterogeneity of the populations, interventions and comparison groups, we conclude that there are insufficient data to draw firm conclusions on the clinical effect of LLLT for low-back pain.”
WALT per-joint dose window: 4-8 J at 785-860 nm or 1-3 J at 904 nm per treatment spot; knee medial 12 J total, hip 12 J, glenohumeral 8 J
Wavelengths (nm)
780 · 810 · 830 · 860 · 904
Irradiance
5-500 mW (780-860 nm); >5 mW/cm² (904 nm)
Sessions / week
2-3
Duration → outcome
4-8 weeks
Bjordal 2003 systematic review (11 acceptable-quality RCTs across knee, TMJ, zygapophyseal joints) found LLLT within the WALT dose window produced a 29.8 mm VAS reduction vs placebo, while studies using doses below the WALT range showed no effect — confirming biphasic dose-response. Stausholm 2019 anchors the canonical knee-OA dose, and Clijsen 2017 confirms LLLT effectively reduces pain in adult musculoskeletal disorders when WALT-aligned.
3 caveats + limitations
Hip OA is under-represented in the literature; most pooled evidence is knee OA.
Heterogeneity across joints — not a homogeneous condition.
Doses outside the WALT window have repeatedly failed to show effect.
5-6 J per spot at 50-200 mW (Leal-Junior 2015); cluster protocols 20-60 J total per muscle group; whole-body PBMT beds deliver 20-30 J/cm² over large area
Wavelengths (nm)
630 · 660 · 808 · 830 · 850 · 905
Irradiance
50-200 mW per diode (100 mW/diode optimal vs 200 mW per Lanferdini 2017)
Minutes / session
30 sec - 5 min per muscle group, pre-exercise
Sessions / week
Single pre-exercise dose; if training daily, dose daily
Duration → outcome
Acute effect within 24 hours post-exercise
Leal-Junior 2015 (Lasers in Medical Science) found that phototherapy applied BEFORE exercise improves muscle performance and accelerates recovery; effective protocols used red or infrared wavelengths, 50-200 mW, and 5-6 J per spot. Li 2024 meta-analysis (34 RCTs) confirms pre-exercise PBM significantly enhances muscle endurance with moderate-to-large effect sizes, and the 2024 sports-medicine umbrella review (Cells/Sports MDPI) confirms reduced muscle soreness at 24 hours post-intervention.
3 caveats + limitations
Pre-exercise PBM has stronger evidence than post-exercise application.
No benefit reported in already highly-trained athletic populations (Li 2024).
No ACSM or FIMS position statement on PBM for muscle recovery — strong evidence base but absent formal society endorsement.
References (2)
Leal-Junior ECP, Vanin AA, Miranda EF, de Carvalho Pde T, Dal Corso S, Bjordal JM (2015). Lasers in Medical Science. PMID:24249354 · DOI · meta-analysis
“Phototherapy (with lasers and LEDs) improves muscular performance and accelerate recovery mainly when applied before exercise. Most of the studies that achieved positive results employed red or infrared wavelengths and phototherapy application before exercises, power outputs between 50 and 200 mW and doses of 5 and 6 J per point (spot).”
Li BM, Qiu DY, Ni PS, et al. (2024). Lasers in Medical Science. PMID:38758297 · meta-analysis
LED-array protocols 1-10 J/cm² per session; cumulative ~30 J/cm² over 30 sessions reported in landmark trials; clinical 660 nm + 830/850 nm combinations 20-30 J/cm² range
Wavelengths (nm)
590 · 630 · 633 · 660 · 830 · 850
Minutes / session
10-20 min per session
Sessions / week
2-3 (clinical) or daily 3-5 min (home use)
Duration → outcome
8-12 weeks
Ngoc 2023 meta-analysis (31 dermatology studies) found red and near-infrared LEDs produce statistically significant improvements in skin rejuvenation, photoaging, and wrinkle reduction. Glass 2021 (Aesthetic Surgery Journal) systematic review concluded a reasonable body of clinical-trial evidence supports LLLT for skin rejuvenation but noted unclear equivalence between LED and laser sources.
4 caveats + limitations
LED dose reporting is highly heterogeneous in the literature.
No formal AAD, EADV, or British Association of Dermatologists clinical practice guideline endorses PBM for skin rejuvenation with specific dose recommendations — AAD provides only a consumer-facing safety acknowledgment.
WALT dose chart does not cover skin rejuvenation.
Home-use device evidence is weaker than clinical LED-array evidence.
References (2)
Ngoc LTN, Moon JY, Lee YC (2023). Photodermatology, Photoimmunology & Photomedicine. PMID:36310510 · DOI · meta-analysis
“LEDs are useful for dermatology and could be potential candidates for future cosmetic applications.”
Glass GE (2021). Aesthetic Surgery Journal. PMID:33471046 · DOI · systematic-review
“A reasonable body of clinical trial evidence exists to support the use of LLLT for skin rejuvenation, the treatment of acne and the treatment of alopecia.”
Combined 415 nm blue + 630-660 nm red LED — blue 48 J/cm²/session and red 633 nm ~96 J/cm² in PDT-adjacent protocols; LED masks 4-10 J/cm² over longer exposure; total 30-60 J/cm² cumulative across 8-12 sessions
Wavelengths (nm)
415 · 630 · 633 · 660 · 830
Sessions / week
1-3
Duration → outcome
8-12 weeks
Ngoc 2023 LED meta-analysis reported a statistically significant SMD of −2.42 favoring blue + red LED for acne, and Wu 2021 meta-analysis (13 RCTs, n=422) found red light therapy reduces moderate-to-severe acne with comparable efficacy to conventional therapy and minimal adverse events. However the 2024 AAD acne guideline concluded "available evidence was insufficient to develop recommendations for procedures such as chemical peels, laser and light-based devices" and issued a conditional recommendation against adding broadband / intense pulsed light to topical adapalene.
4 caveats + limitations
AAD 2024 explicitly declined to endorse light-based devices for acne due to insufficient evidence — this society position is a NEGATIVE finding that must accompany any PBM-for-acne claim.
Blue light (415 nm) is the primary anti-P. acnes mechanism; red light (633 nm) is anti-inflammatory; combinations are superior to either alone.
No Cochrane / Lancet / NEJM / Annals meta-analysis on LLLT specifically for acne vulgaris.
At-home LED devices have less robust evidence than clinical devices.
References (4)
Ngoc LTN, Moon JY, Lee YC (2023). Photodermatology, Photoimmunology & Photomedicine. PMID:36310510 · DOI · meta-analysis
“Both red and blue LED lights play an important role in the treatment of acne vulgaris with an overall statistically significant SMD of −2.42 [−2.64, −2.15] and I2 = 17% < 50%.”
Wu Y, Deng Y, Huang P (2021). Journal of Cosmetic Dermatology. PMID:34363730 · meta-analysis
3-4 J/cm² per session typical home-device dose; 650 nm at ~5 mW per diode, 8-25 minute sessions per FDA-cleared device parameters
Wavelengths (nm)
630 · 650 · 655 · 660 · 670 · 678
Minutes / session
8-25 minutes per session (device-dependent)
Sessions / week
3-7 (low-frequency subgroup superior per Liu 2019)
Duration → outcome
16-26 weeks
Liu 2019 (Lasers in Medical Science) meta-analysis of 8 trials / 11 comparisons found LLLT significantly increased hair density vs sham (SMD 1.32) in both sexes, with both comb- and helmet-type devices effective. FDA has cleared multiple at-home red-light devices for AGA since 2007, and ISHRS recognizes LLLT as a non-pharmacological option suitable as adjunct or alternative to minoxidil/finasteride.
4 caveats + limitations
Most published trials are sponsored by device manufacturers.
Low-frequency treatment subgroups outperformed high-frequency in Liu 2019.
Long-term durability beyond 26 weeks is under-studied.
No formal AAD clinical practice guideline; operative framework is FDA device clearance plus ISHRS position statement.
References (3)
Liu KH, Liu D, Chen YT, Chin SY (2019). Lasers in Medical Science. PMID:30706177 · DOI · meta-analysis
“LLLT significantly increased hair density in AGA. The meta-analysis suggests that low treatment frequency by LLLT have a better hair growth effect than high treatment frequency.”
Lueangarun S, Visutjindaporn P, Parcharoen Y, et al. (2021). Journal of Clinical and Aesthetic Dermatology. PMID:34980962 · meta-analysis
Glass GE (2021). Aesthetic Surgery Journal. PMID:33471046 · DOI · systematic-review
Diabetic foot ulcer protocols 3-8 J/cm² per session; broader 1-10 J/cm² for general wounds; oral surgery sites 1-4 J/point across 3-6 points
Wavelengths (nm)
410 · 630 · 660 · 685 · 808 · 830 · 904 · 940
Sessions / week
3-5
Duration → outcome
4-12 weeks
Zhou 2021 meta-analysis of LLLT for diabetic foot ulcers reported 30.9% reduction in ulcer area and 4.65x greater complete-healing odds vs control, and Taha/Mokhtari 2024 meta-analysis of 18 RCTs (n=670) found significantly greater wound-size reduction and pain relief. However the 2000 Cochrane review (Flemming & Cullum) on venous leg ulcers found NO benefit, and major wound-care bodies (IWGDF 2023 Diabetic Foot, WHS 2024) declined to include PBM among recommended interventions.
4 caveats + limitations
Cochrane 2000 venous leg ulcer review is NEGATIVE — no benefit found.
IWGDF 2023 diabetic foot guideline and WHS 2024 update reviewed evidence and did NOT include PBM in their recommended intervention list (strong implicit negative).
Skin pigmentation affects penetration.
Both supportive meta-analyses acknowledge "no recommendation for best treatment parameters" — dose protocols vary widely.
References (3)
Zhou Y, Chia HWA, Tang HWK, et al. (2021). Wound Repair and Regeneration. PMID:33078478 · meta-analysis
Mokhtari F, Modaberi A, Zandi A, Aalaei S, Vatandust J (2024). Cureus. PMID:39610644 · DOI · meta-analysis
“LLLT results in significant reduction in wound size, increased rate of complete wound healing, and pain reduction.”
Flemming K, Cullum N (2000). Cochrane Database of Systematic Reviews. PMID:10796615 · DOI · cochrane
“We have found no evidence of any benefit associated with low level laser therapy on venous leg ulcer healing.”
no consensus dose — varies by anatomic target; WALT 2022 904 nm chart framed as anti-inflammatory dosing per joint/tendon site only
Wavelengths (nm)
630 · 660 · 810 · 830 · 850 · 905
The Son 2025 umbrella review (15 meta-analyses, 204 RCTs, 35 endpoints) found PBM effective for several inflammation-driven endpoints (fibromyalgia, osteoarthritis-related disability) at low-to-moderate certainty. Mechanism via cytochrome-c-oxidase activation and downregulation of TNF-α / IL-6 / IL-1β is well-established at the bench level, but no clinical body has issued guidance on PBM for "general systemic inflammation" as a unitary indication.
3 caveats + limitations
No high-impact systematic review or society position addresses "PBM for general systemic inflammation" as a discrete clinical endpoint.
Claims about inflammation must be supported via condition-specific evidence (RA, OA, tendinopathy) rather than as a unified category.
WALT 2022 chart frames its dosing as anti-inflammatory but only at specific anatomic sites — no general inflammation dose exists.
References (1)
Son Y, Yon DK, et al. (2025). Systematic Reviews. PMID:40770824 · systematic-review
CIPN protocols converge on ~6 J/cm² per handheld diode point; diabetic peripheral neuropathy 4-8 J/cm² per foot-grid point; total 4-10 J/cm² per session
Wavelengths (nm)
635 · 808 · 810 · 830 · 850 · 904
Sessions / week
2-3
Duration → outcome
4-8 weeks
PBM trials in chemotherapy-induced peripheral neuropathy (CIPN) consistently show reductions in neuropathy severity and pain; the ASCO 2020 guideline (Loprinzi) rates PBM "moderate benefit" and the WALT 2022 cancer side-effects position paper covers CIPN at expert-consensus level. Erchonia FX-635 secured FDA clearance for diabetic peripheral neuropathy in 2017. However the AAN painful diabetic neuropathy guideline and the ADA Standards of Care do not endorse PBM, and no completed high-impact Cochrane / Lancet / BMJ / JAMA / NEJM systematic review on PBM for DPN exists.
4 caveats + limitations
No completed high-impact Cochrane / Lancet / BMJ / JAMA / NEJM systematic review on PBM for peripheral neuropathy.
AAN, ADA, and AACE pharmacotherapy guidelines exclude PBM.
CIPN evidence is stronger than DPN evidence at the meta-analysis level; DPN meta-analyses remain protocol-stage as of 2024.
Heterogeneous parameters across CIPN trials.
References (1)
Loprinzi CL, Lacchetti C, Bleeker J, et al. (2020). Journal of Clinical Oncology. PMID:30508986 · guideline
WALT recommendation per tendon site: supraspinatus / infraspinatus / patellar / Achilles / plantar 8 J total at 780-860 nm (min 4 J/point); 2-4 J total at 904 nm (2022 revision); effective range 0.5-7.2 J/point total per Bjordal 2008
Wavelengths (nm)
632 · 810 · 820 · 830 · 904
Irradiance
max 100 mW/cm² (Achilles, iliotibial, lateral epicondyle per WALT)
Sessions / week
2-3
Duration → outcome
2-4 weeks (short-term effect)
Tumilty 2010 systematic review (25 RCTs) found LLLT can be effective when WALT-recommended doses are used; 12 positive studies clustered at the recommended dose window. Yap 2025 meta-analysis confirms short-term pain relief in chronic tendinopathy, with greater session counts correlating with greater pain relief.
4 caveats + limitations
APTA 2024 Achilles tendinopathy CPG (JOSPT) explicitly recommends AGAINST LLLT for midportion Achilles tendinopathy — this site-specific NEGATIVE position must accompany any general tendinopathy claim.
Inadequate doses produce null results; the WALT window must be observed.
Site-specific evidence (lateral epicondyle, supraspinatus) is more robust than "general tendinopathy."
Long-term effect beyond 4 weeks is unclear.
References (2)
Tumilty S, Munn J, McDonough S, Hurley DA, Basford JR, Baxter GD (2010). Photomedicine and Laser Surgery. PMID:19708800 · DOI · systematic-review
“LLLT can potentially be effective in treating tendinopathy when recommended dosages are used. The 12 positive studies provide strong evidence that positive outcomes are associated with the use of current dosage recommendations for the treatment of tendinopathy.”
Yap BWD, Lim ECW (2025). Journal of Back and Musculoskeletal Rehabilitation. PMID:40437920 · meta-analysis
2-6 J per tender point (typically 18 tender points); whole-body PBMT bed protocols deliver larger total energy
Wavelengths (nm)
670 · 780 · 808 · 830 · 904
Sessions / week
2-3
Duration → outcome
3-6 weeks
Yeh 2019 meta-analysis (9 RCTs, n=325) concluded LLLT is effective, safe, and well-tolerated for fibromyalgia with significant improvements in FIQ, pain, tender points, fatigue, stiffness, depression, and anxiety. Son 2025 umbrella review identified fibromyalgia as the strongest-evidence endpoint for PBM across the conditions reviewed.
4 caveats + limitations
EULAR 2017 fibromyalgia recommendations did NOT endorse LLLT despite reviewing non-pharmacological options — only exercise received a strong-for recommendation.
No Cochrane / Lancet / BMJ / JAMA / NEJM review of LLLT for fibromyalgia exists; Yeh 2019 was published in Pain Physician (specialty journal).
Combined LLLT + exercise outperforms LLLT alone.
Heterogeneous tender-point counts and treatment protocols.
References (3)
Yeh SW, Hong CH, Shih MC, Tam KW, Huang YH, Kuan YC (2019). Pain Physician. PMID:31151332 · DOI · meta-analysis
“LLLT is an effective, safe, and well-tolerated treatment for fibromyalgia.”
Son Y, Yon DK, et al. (2025). Systematic Reviews. PMID:40770824 · systematic-review
Honda Y, Sakamoto J, Nakano J, et al. (2018). Pain Research and Management. PMID:30402199 · meta-analysis
no consensus dose; transcranial PBM pilot RCTs use 810 nm at ~60 J/cm² and 250 mW/cm² × 6 min per site
Wavelengths (nm)
630 · 660 · 810 · 830 · 850
No completed Cochrane / Lancet / BMJ / JAMA / NEJM systematic review on red/NIR PBM for sleep disorders exists. The van Maanen 2016 meta-analysis confirmed broad light-therapy efficacy for sleep problems (g=0.47) but addressed bright/blue visible light for circadian phase shifting, which is mechanistically distinct from red/NIR PBM. Direct red/NIR sleep evidence is preliminary — limited to small pilot RCTs of transcranial PBM.
4 caveats + limitations
AASM endorses bright (10,000 lux) light therapy for circadian disorders — this is mechanistically distinct from red/NIR PBM and must NOT be conflated.
No formal society guideline on red/NIR PBM for sleep.
No high-impact systematic review or meta-analysis on PBM for insomnia or circadian disorders.
Active pipeline searches optimal protocol; tPBM and upper-airway PBM are competing approaches.
References (1)
van Maanen A, Meijer AM, van der Heijden KB, Oort FJ (2016). Sleep Medicine Reviews. PMID:26606319 · meta-analysis
Dental third-molar sites 1-4 J/point across 3-6 points; broader 1-10 J/cm² for general surgical sites; total knee arthroplasty dual-wavelength pilot devices
Wavelengths (nm)
630 · 660 · 808 · 810 · 830 · 904 · 940
Sessions / week
daily early, 3-5 after
Duration → outcome
1-4 weeks
Mokhtari 2024 meta-analysis (18 RCTs, n=670 skin wounds including post-surgical) found significant wound-size reduction and pain relief with LLLT. Procedure-specific evidence (gingivectomy, third-molar extraction, bariatric, oral wounds) shows consistent pain reduction and accelerated healing.
4 caveats + limitations
No Cochrane / Lancet / BMJ / JAMA / NEJM systematic review on PBM for general post-surgical recovery.
AAOS 2025 Rotator Cuff CPG does NOT address PBM for post-surgical rotator-cuff recovery.
WALT chart does not include post-surgical recovery as a discrete indication.
Surgery-type-specific evidence (dental, bariatric, oral) is more robust than "general post-surgical."
References (2)
Mokhtari F, Modaberi A, Zandi A, Aalaei S, Vatandust J (2024). Cureus. PMID:39610644 · DOI · meta-analysis
“LLLT results in significant reduction in wound size, increased rate of complete wound healing, and pain reduction.”
Memarian A, Vosoughi AR, Hadianfard MJ, et al. (2023). Photobiomodulation, Photomedicine, and Laser Surgery. PMID:37583501 · meta-analysis
WALT-aligned, condition-specific: 4-8 J at 785-860 nm or 1-3 J at 904 nm per spot for musculoskeletal chronic pain; chronic neck pain cluster protocols 30-60 J total
Wavelengths (nm)
660 · 780 · 810 · 820 · 830 · 904
Sessions / week
2-3
Chow 2009 (The Lancet) meta-analysis found LLLT reduces pain immediately after treatment in acute neck pain and up to 22 weeks after completion of treatment in chronic neck pain. Clijsen 2017 meta-analysis concluded LLLT effectively reduces pain in adult musculoskeletal disorders, with adherence to WALT dose guidelines substantially enhancing effectiveness.
4 caveats + limitations
"Chronic pain" is a heterogeneous umbrella; condition-specific dosing matters and WALT only covers musculoskeletal anatomic sites.
IASP has not issued a formal clinical recommendation or position on PBM for chronic pain.
The Lancet evidence base is for chronic neck pain specifically — not all chronic-pain subtypes.
WALT-aligned trials show larger effects than non-aligned trials.
References (2)
Chow RT, Johnson MI, Lopes-Martins RAB, Bjordal JM (2009). The Lancet. PMID:19913903 · DOI · meta-analysis
“LLLT reduces pain immediately after treatment in acute neck pain and up to 22 weeks after completion of treatment in patients with chronic neck pain.”
Clijsen R, Brunner A, Barbero M, Clarys P, Taeymans J (2017). European Journal of Physical and Rehabilitation Medicine. PMID:28145397 · meta-analysis
WALT supraspinatus / infraspinatus: 8 J total (780-860 nm), min 4 J/point; 2 J total at 904 nm with min 2 J/point (2022 revision); glenohumeral joint 2-4 points 8 J (780-860 nm) or 3 J (904 nm)
Wavelengths (nm)
632 · 780 · 810 · 820 · 830 · 904
Sessions / week
2-3
Duration → outcome
3-6 weeks
Haslerud 2015 meta-analysis (17 RCTs) found optimal-dose LLLT delivers clinically-relevant pain relief in shoulder tendinopathy (12.80-20.41 mm VAS) — trials with inadequate doses were ineffective across all outcomes. The 2016 Cochrane review (Page et al.) found low-quality evidence that LLLT may improve overall pain and function more than placebo at short-term in calcific tendinitis.
4 caveats + limitations
AAOS 2025 Rotator Cuff CPG does NOT address PBM as a discrete intervention.
Adequate dose is the critical determinant — inadequate-dose trials uniformly failed.
LLLT + physiotherapy outperforms LLLT alone.
Cochrane evidence in shoulder tendinopathy is rated low quality.
References (1)
Haslerud S, Magnussen LH, Joensen J, Lopes-Martins RAB, Bjordal JM (2015). Physiotherapy Research International. PMID:25450903 · DOI · meta-analysis
“Optimal LLLT can offer clinically relevant pain relief and initiate a more rapid course of improvement, both alone and in combination with physiotherapy interventions.”
no consensus dose; RCTs use 3-6 J/cm² over shoulder periarticular points; WALT glenohumeral 8 J (780-860 nm) or 3 J (904 nm) is the closest analog
Wavelengths (nm)
808 · 830 · 850 · 904
Sessions / week
3-5
Duration → outcome
4-8 weeks
No dedicated LLLT-only meta-analysis exists for adhesive capsulitis. Most evidence consists of individual RCTs or HILT-focused meta-analyses; the active pipeline (5 completed, 2 active trials) is shifting from LLLT to HILT comparators. LLLT shows pain and ROM improvement when combined with exercise, but the evidence base is preliminary.
4 caveats + limitations
No high-impact Cochrane / Lancet / BMJ / JAMA / NEJM systematic review specifically on PBM for adhesive capsulitis.
Cochrane has Page et al. 2014 electrotherapy review (PMID 25271097) that includes LLLT but did not find sufficient evidence as a discrete arm.
No formal society CPG addresses PBM dose for frozen shoulder specifically.
HILT may outperform LLLT in the active trial pipeline.
References (1)
Cha JY, Kim YT, Park JK (2023). Journal of Physical Therapy Science. PMID:37981583 · meta-analysis
WALT carpal-tunnel: 8 J total / 4 J per point (780-860 nm); 2 J total / 1 J per point (904 nm 2022 revision); typical session 9-18 J across multiple points
Wavelengths (nm)
780 · 808 · 830 · 850 · 904
Sessions / week
3-5
Duration → outcome
3-4 weeks (assessed at 12 weeks)
Li 2016 meta-analysis showed LLLT modestly improved grip strength, VAS pain, and SNAP at 12-week follow-up for mild-to-moderate CTS, and Franke 2017 confirmed effect on pain and function vs placebo. However the 2017 Cochrane review (Rankin et al.) found very-low-quality evidence with no data to support a clinical effect of LLLT in CTS, and the AAOS 2024 Carpal Tunnel CPG explicitly states "evidence suggests that laser therapy does not improve long-term patient reported outcomes for carpal tunnel syndrome."
4 caveats + limitations
Cochrane 2017 (Rankin et al.) NEGATIVE — "no data to support any clinical effect of LLLT in treating CTS."
AAOS 2024 Carpal Tunnel CPG NEGATIVE — explicitly does not endorse laser therapy.
Effect, where present in positive meta-analyses, confined to mild-to-moderate CTS.
Heterogeneous parameter selection across trials; positive findings driven by small studies with significant risk of bias.
References (3)
Rankin IA, Sargeant H, Rehman H, Gurusamy KS (2017). Cochrane Database of Systematic Reviews. PMID:35611937 · DOI · cochrane
“The evidence is of very low quality and we found no data to support any clinical effect of LLLT in treating CTS. Only VAS pain and finger-pinch strength met previously published MCIDs but these are likely to be overestimates of effect given the small studies and significant risk of bias.”
Li ZJ, Wang Y, Zhang HF, Ma XL, Tian P, Huang Y (2016). Medicine (Baltimore). PMID:27495063 · meta-analysis
no consensus dose — extrapolated from shoulder tendinopathy WALT (8 J 780-860 nm / 2 J 904 nm) and trochanter major dose (2-3 points 2 J at 904 nm or 2-4 points 8 J at 780-860 nm)
Wavelengths (nm)
830 · 904
No dedicated LLLT meta-analysis for bursitis exists, and zero ClinicalTrials.gov entries are explicitly tagged "bursitis" + PBMT/LLLT/RLT. The closest pooled evidence is the Haslerud 2015 shoulder tendinopathy meta-analysis (which includes subacromial impingement / bursitis anatomy). Trochanteric bursitis specifically is absent from systematic reviews.
4 caveats + limitations
No high-impact systematic review or society CPG addresses PBM for bursitis as a standalone indication.
WALT chart has no discrete bursitis entry — only adjacent-tendon dosing.
Zero registered trials specifically study PBMT/LLLT/RLT for bursitis.
Trochanteric bursitis evidence is absent in systematic reviews.
References (1)
Haslerud S, Magnussen LH, Joensen J, Lopes-Martins RAB, Bjordal JM (2015). Physiotherapy Research International. PMID:25450903 · DOI · meta-analysis
WALT lateral epicondylitis: 4 J total at 780-860 nm across 1-2 points or 1 J at 904 nm (2022 revision); effective dose subgroup 0.5-7.2 J/point per Bjordal 2008
Wavelengths (nm)
632 · 810 · 830 · 904
Irradiance
max 100 mW/cm² (lateral epicondylitis WALT cap)
Sessions / week
2-3
Duration → outcome
3-4 weeks (short-term)
Bjordal 2008 meta-analysis (13 of 18 RCTs, n=730) found LLLT at 904 nm (and possibly 632 nm) applied directly to lateral elbow tendon insertions provides short-term pain relief (17.2 mm VAS at 904 nm) and improved grip strength, both alone and as exercise adjunct. APTA 2022 Lateral Elbow Pain CPG addresses LLLT among modalities, and WALT provides specific dose recommendations.
4 caveats + limitations
Applied to tendon insertion, not over muscle belly.
Dose-window is critical — outside-window doses fail.
Most evidence is for lateral epicondylitis; medial epicondylitis is essentially absent in trials.
As sole treatment, "of limited value" per Bjordal — useful as adjunct.
References (1)
Bjordal JM, Lopes-Martins RAB, Joensen J, Couppe C, Ljunggren AE, Stergioulas A, Johnson MI (2008). BMC Musculoskeletal Disorders. PMID:18510742 · DOI · meta-analysis
“LLLT administered with optimal doses of 904 nm and possibly 632 nm wavelengths directly to the lateral elbow tendon insertions, seem to offer short-term pain relief and less disability in LET, both alone and in conjunction with an exercise regimen.”
no consensus dose; RCTs report ~4 J per point as most effective; WALT lumbar spine (16 J total at 780-860 nm or 4 J at 904 nm) is the closest analog
Wavelengths (nm)
808 · 830 · 904
Sessions / week
3-5
Duration → outcome
2-4 weeks
No dedicated meta-analysis for LLLT in sciatica or lumbar radiculopathy exists. The Konstantinovic 2010 RCT found LLLT as adjunct improved acute LBP with radiculopathy, and recent RCTs (Khan 2022; Korkmaz 2024) are consistently positive but not yet pooled. The active pipeline uses HILT rather than LLLT.
4 caveats + limitations
No high-impact Cochrane / Lancet / BMJ / JAMA / NEJM systematic review on PBM for sciatica.
NICE NG59 (2016/2020) does not endorse laser therapy for sciatica and notes "uncertainty regarding the efficacy and effectiveness of laser therapy."
Dose recommendations are extrapolated from chronic low-back-pain literature.
Pipeline is small (3 completed, 2 active) — no big-N pivotal trials yet.
References (2)
Konstantinovic LM, Cutovic MR, Milovanovic AN, et al. (2010). Pain Medicine. PMID:20001318 · rct
Khan M, et al. (2022). Medical Science Monitor. PMID:35265302 · rct
Gomes 2022 systematic review of primary headache RCTs found PBM had a clinically-important pain effect vs sham, but the authors concluded evidence is "insufficient" to support use due to high risk of bias and imprecise estimates. The American Headache Society 2021 consensus statement on neuromodulation reviewed eTNS, nVNS, and sTMS but did NOT include transcranial PBM among recommended modalities.
4 caveats + limitations
AHS 2021 consensus statement reviewed neuromodulation modalities and did NOT include PBM — this society position must accompany any claim.
Most trials are small and at high risk of bias.
No dose consensus.
ClinicalTrials.gov pipeline is dominated by cervicogenic-headache trials, not vascular migraine — different mechanism.
References (1)
Gomes AO, Martimbianco ALC, Brugnera A Jr, et al. (2022). Life (Basel). PMID:35054491 · systematic-review
1-4 J per RA hand joint (WALT finger PIP/MCP: 4 J 780-860 nm or 2 J 904 nm; wrist: 8 J 780-860 nm or 3 J 904 nm)
Wavelengths (nm)
632 · 780 · 810 · 830 · 904
Sessions / week
3-5
Duration → outcome
2-4 weeks
The Brosseau 2005 Cochrane review of LLLT for RA (5 placebo-controlled trials, n=204) found LLLT reduced morning stiffness duration by 27.5 minutes (95% CI 2.9-52) vs placebo, alongside ~70% pain reduction. No significant dose- or wavelength-subgroup differences were detected (likely under-powered).
4 caveats + limitations
Effect is specific to RA-related morning stiffness.
Zero ClinicalTrials.gov trials explicitly target morning stiffness — it is captured only as a secondary outcome inside RA/OA/fibromyalgia trials.
Other inflammatory arthropathies (ankylosing spondylitis, psoriatic arthritis) have not been specifically studied.
Newer Lourinho 2023 is less optimistic on infrared LLLT for RA generally.
References (1)
Brosseau L, Robinson V, Wells G, et al. (2005). Cochrane Database of Systematic Reviews. PMID:16235295 · DOI · cochrane
“LLLT could be considered for short-term treatment for relief of pain and morning stiffness for RA patients, particularly since it has few side-effects.”
WALT plantar fasciitis: 8 J total / 4 J per point (780-860 nm) or 4 J total / 2 J per point (904 nm 2022 revision); typical 4-10 J/cm² per session in trials
Wavelengths (nm)
780 · 808 · 830 · 904
Sessions / week
2-3
Duration → outcome
3-4 weeks (effect persists 3 months)
Wang 2019 meta-analysis (6 RCTs) found LLLT significantly relieves heel pain in plantar fasciitis with effect persisting 3 months post-treatment. Cinar 2021 meta-analysis (14 studies, n=817) confirmed short-term pain reduction. The APTA 2023 Heel Pain — Plantar Fasciitis CPG UPGRADED laser therapy from Grade C (2014) to Grade B, the strongest condition-specific PBM endorsement from a major US clinical body for any musculoskeletal indication.
3 caveats + limitations
Foot Function Index pain subscale did not differ significantly in Wang 2019.
Disability outcomes are mixed across the literature.
No Cochrane / Lancet / BMJ / JAMA / NEJM review specifically on PBM for plantar fasciitis; Wang 2019 published in Medicine (Baltimore) which is mid-tier.
References (2)
Wang W, Jiang W, Tang C, Zhang X, Xiang J (2019). Medicine (Baltimore). PMID:30653125 · DOI · meta-analysis
“This meta-analysis indicates that the LLLT in patients with PF significantly relieves the heel pain and the excellent efficacy lasts for 3 months after treatment.”
Cinar E, Saxena S, Uygur F (2021). Journal of Foot and Ankle Surgery. PMID:34847470 · systematic-review
no consensus dose; pilot studies use transcranial 60 J/cm² and thoracic 6-10 J/cm²; oral PBMT 1-4 J/point
Wavelengths (nm)
660 · 808 · 810 · 830 · 850 · 940
No published meta-analysis or systematic review with quantitative pooled data on PBM for long COVID exists. Fekrazad 2021 hypothesized a PBM rationale in an editorial, Salehpour 2024 transcranial PBM review provides indirect mechanistic support, and only 2 small completed pilot RCTs (n<15 each) are registered on ClinicalTrials.gov with no active pipeline.
4 caveats + limitations
No meta-analysis exists — strongest references are editorials and protocol papers.
No major medical society has issued a formal recommendation; WALT has not published a position paper on long COVID.
PBM for long COVID is exploratory only and must not be cited as evidence-based.
Major unmet evidence opportunity given prevalence — but absence of evidence is not evidence of efficacy.
References (2)
Fekrazad R, Fekrazad S (2021). Photobiomodulation, Photomedicine, and Laser Surgery. PMID:33497594 · systematic-review
Salehpour F, Khademi M, Vazifehkhah S, Mahmoudi J (2024). Lasers in Medical Science. PMID:38317779 · systematic-review
~10 J/cm² per facial point (Ordahan 2017 protocol); 4-6 J/point on affected hemiface acupoints at 808/904 nm in active trials; 8-20 J/cm² in pooled meta-analyses
Wavelengths (nm)
660 · 808 · 830 · 850 · 904 · 905
Sessions / week
3
Duration → outcome
3-6 weeks
Ordahan 2017 RCT established 830 nm at 10 J/cm² 3x/wk for 6 weeks significantly improved facial disability index vs exercise alone. Amiri & Fekrazad 2024 (Lasers in Medical Science) systematic review confirmed PBM improves facial muscle function, pain intensity, and muscle strength in Bell’s palsy, with 830-850 nm and combined 808/905 nm yielding the most favorable results.
4 caveats + limitations
Cochrane 2011 review of physical therapy for Bell’s palsy (Teixeira et al.) found insufficient evidence to recommend specific modalities including laser; mostly high risk of bias.
AAN/AAO-HNSF 2013 joint Bell’s palsy guideline does not address PBM/laser as a graded recommendation.
Adjunctive to exercise/conventional therapy, not standalone.
Most trials are small.
References (3)
Amiri P, Fekrazad R (2024). Lasers in Medical Science. PMID:39627559 · DOI · systematic-review
“Photobiomodulation therapy can improve facial muscle function, pain intensity, and muscle strength in Bell’s palsy patients. Notably, wavelengths of 830-850 nm and the combination of 808/905 nm yielded the most favorable results.”
Ordahan B, Karahan AY (2017). Lasers in Medical Science. PMID:28337563 · rct
Zhang Y, et al. (2024). Lasers in Medical Science. PMID:39546047 · meta-analysis
Last reviewed: 2026-05-30
How to cite this table
Hale Health Research. PBM Dose Canonical Table, version 1.0.0. Hale Health; 2026-05-30. Available from: https://thehale.ca/research/pbm-dose-canonical-table
Released under CC BY 4.0. You may reuse this table in any medium, including clinical-practice handouts, academic articles, and AI-assisted research tools, with attribution.
This report is educational. It does not replace medical advice or clinician judgment, and the dose ranges here should not be applied without considering individual patient context, comorbidities, and medication interactions. PBM is generally well-tolerated but can be contraindicated in specific scenarios listed above. Consult a qualified healthcare provider before starting any new therapy.